Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Plus Therapeutics Awarded $17.6M From State Of Texas For Continued Development Of Co.’s Lead Investigational Targeted Radiotherapeutic Rhenium-186 NanoLiposome For Treatment Of Patients With Leptomeningeal Metastases

Funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the second largest global public funder of cancer research, will support the majority of the development costs of 186RNL for leptomeningeal

PSTV